In his work with clients in pharma, biotech, medical device, diagnostics and technology, Devin brings knowledge in laboratory and clinical trial implementation and management, regulatory oversight and hospital wide quality improvement initiatives garnered from his experience working in two major health systems. Prior to joining the firm he worked for the Anne & Robert H. Lurie Children’s Hospital of Chicago and the Johns Hopkins School of Medicine where he managed clinical and pharmaceutical trials, including protocol implementation, data collection and regulatory control procedures in accordance with FDA, GCP, and IRB guidelines. In his role he performed both clinical and laboratory based research in pediatric hematology, focusing mainly on Sickle Cell Disease and hemophilia.
As an undergraduate at Princeton University, Devin worked in the laboratory of Thomas J. Silhavy, researching membrane biogenesis and signal transduction in Escherichia coli. Specifically, he investigated the manner in which SurA, a chaperone protein in E. coli, is involved in the folding and assembly of outer membrane proteins, culminating in a thesis titled “A SurA independent outer membrane protein, PldA, shows no chaperone specificity for transport and assembly in Escherichia coli.”
Devin’s background in laboratory and clinical research and experience from an internal health care system perspective proves invaluable in his work with clients in licensing, collaboration and corporate matters.
Representative Legal Matters
Represented Takeda in its collaboration and license agreement with Poseida Therapeutics to utilize Poseida’s piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle delivery technology and genetic engineering platforms for up to eight gene therapy programs, including Hemophilia A.
Represented Takeda in its strategic collaboration with KSQ Therapeutics to identify optimal T cell and NK cell gene targets screened using KSQ’s CRISPRomics technology and to develop and commercialize novel cell and non-cell immuno-oncology therapies.
Represented Affirm, Inc. on its acquisition of Returnly Technologies, Inc. for approximately USD 300 million and numerous other strategic transactions.
Represented Uniphore Technologies Inc., a conversational AI platform providing automation, analytics, assistant and security services, in its acquisition of Jacada Ltd.
Advised Coinbase on numerous strategic transactions.
Represented Takeda in the sale to Neuraxpharm of global rights to the prescription brand Buccolam® (indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures).
Professional Associations and Memberships
- Chicago Bar Association
- Illinois~United States (2018)
- University of Chicago Law School (JD, with Honors) (2018)
- Princeton University (AB Molecular Biology) (2010)
Co-author, “Perfect Partners: How pharma and biotech can get the best out of licensing and collaborations,” Intellectual Property Magazine, April 2020
“Feasibility and safety of home exercise training in children with sickle cell anemia”, co-author, Pediatric Blood & Cancer, 9 December 2017
“Self-Reported Physical Activity and Exercise Patterns in Children with Sickle Cell Disease”, co-author, Pediatric Exercise Science, 22 May 2017
“Opioid Prescription Practices at Discharge and 30-Day Returns in Children with Sickle Cell Disease and Pain”, co-author, Pediatric Blood & Cancer,1 November 2016
“Personalized Reminders Increase Screening for Stroke Risk in Children with Sickle Cell Anemia”, co-author, Southern Medical Journal, 9 September 2016
“Habitual Physical Activity and Exercise Patterns in Children and Adolescents with Sickle Cell Disease” co-author, American Society of Hematology Blood Journal, 4 December 2014